Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,748Revenue $M318Net Margin (%)-35.8Altman Z-Score10.1
Enterprise Value $M3,011EPS $-1.0Operating Margin %-35.9Piotroski F-Score3
P/E(ttm)--Beneish M-Score-1.9Pre-tax Margin (%)-35.8Higher ROA y-yN
Price/Book5.110-y EBITDA Growth Rate %-4.9Quick Ratio6.3Cash flow > EarningsN
Price/Sales10.65-y EBITDA Growth Rate %-12.7Current Ratio6.7Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-19.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-30.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M139ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with SGEN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SGENVanguard Health Care Fund 2015-12-31 Sold Out -0.01%$37.16 - $45.52
($41.72)
$ 26.87-36%Sold Out0
SGENVanguard Health Care Fund 2015-06-30 Buy 0.02%$34.03 - $49.63
($41.17)
$ 26.87-35%New holding170,125
SGENFirst Eagle Investment 2010-03-31 Sold Out -0.01%$9.34 - $12.59
($10.84)
$ 26.87148%Sold Out0
SGENFirst Eagle Investment 2009-12-31 Buy 0.01%$8.74 - $13.16
($9.69)
$ 26.87177%New holding67,373
SGENBill Gates 2009-09-30 Sold Out -0.39%$8.75 - $14.8
($11.69)
$ 26.87130%Sold Out0
SGENFirst Eagle Investment 2009-06-30 Sold Out -0.01%$8.18 - $10.34
($9.08)
$ 26.87196%Sold Out0
SGENFirst Eagle Investment 2009-03-31 Add$7.23 - $10.36
($9.4)
$ 26.87186%Add 40.00%70,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SGEN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
HIMES VAUGHN BEVP, Proc Svcs & Tech Ops 2015-12-15Sell40,500$39.94-32.72view
SIEGALL CLAY BPresident and CEO 2015-12-03Sell3,720$39.99-32.81view
BAKER FELIXDirector, 10% Owner 2015-11-20Buy329,358$43.94-38.85view
SIEGALL CLAY BPresident and CEO 2015-11-17Sell87,473$45.4-40.81view
Cline Darren SSVP, Commercial 2015-11-11Sell5,769$45.68-41.18view
BAKER FELIXDirector, 10% Owner 2015-11-10Buy934,624$42.95-37.44view
DOBMEIER ERICCOO 2015-11-06Sell17,452$42.5-36.78view
GRYSKA DAVID WDirector 2015-11-05Sell10,000$43.57-38.33view
SIEGALL CLAY BPresident and CEO 2015-11-04Sell3,718$43.14-37.71view
SIEGALL CLAY BPresident and CEO 2015-10-05Sell3,718$41.3-34.94view

Quarterly/Annual Reports about SGEN:

    News about SGEN:

    Articles On GuruFocus.com
    Insiders Are Buying Barnes & Noble Sep 18 2015 
    Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
    Insiders keep on buying Macerich Co and Seattle Genetics May 22 2015 
    Insiders new buys : ZU, SGEN, MAC, SHLD, TBRA May 12 2015 
    Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
    Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
    Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
    Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
    Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN Sep 10 2012 
    WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS Sep 03 2012 

    More From Other Websites
    Seattle Genetics' (SGEN) Q4 Loss Wider than Expected Feb 10 2016
    Cantor Upgrades Seattle Genetics To Buy, Firm Says Guidance Is Conservative Feb 10 2016
    Seattle Genetics upgraded by Cantor Fitzgerald Feb 10 2016
    Edited Transcript of SGEN earnings conference call or presentation 9-Feb-16 9:30pm GMT Feb 10 2016
    Seattle Genetics reports 4Q loss Feb 09 2016
    Seattle Genetics reports 4Q loss Feb 09 2016
    Seattle Genetics revenue jumps as cancer drug Adcetris takes off Feb 09 2016
    SEATTLE GENETICS INC /WA Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 09 2016
    4:09 pm Seattle Genetics beats by $0.01, beats on revs; guides FY16 revs in-line Feb 09 2016
    Seattle Genetics Reports Fourth Quarter and Year 2015 Financial Results Feb 09 2016
    Q4 2015 Seattle Genetics Inc Earnings Release - After Market Close Feb 09 2016
    [$$] Two Biotechs to Buy During Earnings Week Feb 08 2016
    [$$] Today's Top 5 Stock Picks: Solid Profits, Discounted Feb 04 2016
    Seattle Genetics Announces Commercial and Regulatory Progress under ADCETRIS® (Brentuximab Vedotin)... Feb 04 2016
    Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date? Feb 01 2016
    SEATTLE GENETICS INC /WA Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Jan 29 2016
    Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2015... Jan 20 2016
    This Biotech CEO Made Investors 7x On His Last Deal Jan 12 2016
    Biotech Exec Took A Company From $2 to $14, Before Starting On This New Deal Jan 12 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK